Sarepta Therapeutics (SRPT) Gains from Sales and Divestitures (2010 - 2025)
Sarepta Therapeutics' quarterly Gains from Sales and Divestitures came in at $225000.0 in Q4 2025, up 407.9% year-on-year from $44300.0 in Q4 2024, and up 491.33% quarter-over-quarter from $38050.0 in Q3 2025.
Sarepta Therapeutics has reported Gains from Sales and Divestitures for 16 years, with the latest figure at $225000.0 in Q4 2025.
- For the quarter ending Q4 2025, Gains from Sales and Divestitures rose 407.9% year-over-year to $225000.0; the trailing twelve-month figure through Dec 2025 stood at $225000.0 (up 407.9% YoY), and the FY2025 full-year result was $225000.0, up 407.9% from the prior year.
- Gains from Sales and Divestitures for Q4 2025 stood at $225000.0, up from $38050.0 in the prior quarter.
- The five-year high for Gains from Sales and Divestitures was $644614.0 in Q4 2023, with the low at $38050.0 in Q2 2025.
- Average Gains from Sales and Divestitures over 5 years is $214033.0, with a median of $134650.0 recorded in 2024.
- Year-over-year, Gains from Sales and Divestitures slumped 93.13% in 2024 and jumped 407.9% in 2025.
- Tracing SRPT's Gains from Sales and Divestitures over 5 years: stood at $276980.0 in 2021, then jumped by 40.72% to $389761.0 in 2022, then soared by 65.39% to $644614.0 in 2023, then sank by 93.13% to $44300.0 in 2024, then jumped by 407.9% to $225000.0 in 2025.
- The last three Gains from Sales and Divestitures figures came in at $225000.0 (Q4 2025), $38050.0 (Q3 2025), and $38050.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Sarepta Therapeutics | 1.86 Bn | 1.17 Bn | 291.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 225,000.00 |
| Dec 31, 2025 | 225,000.00 |
| Sep 30, 2025 | 38,050.00 |
| Sep 30, 2025 | 38,050.00 |
| Jun 30, 2025 | 38,050.00 |
| Jun 30, 2025 | 38,050.00 |
| Dec 31, 2024 | 44,300.00 |
| Dec 31, 2024 | 44,300.00 |
| Sep 30, 2024 | 44,300.00 |
| Sep 30, 2024 | 44,300.00 |
| Jun 30, 2024 | 44,300.00 |
| Jun 30, 2024 | 44,300.00 |
| Dec 31, 2023 | 644,614.00 |
| Dec 31, 2023 | 644,614.00 |
| Jun 30, 2023 | 394,975.00 |
| Jun 30, 2023 | 394,975.00 |
| Dec 31, 2022 | 389,761.00 |
| Dec 31, 2022 | 389,761.00 |
| Dec 31, 2021 | 276,980.00 |
| Dec 31, 2021 | 276,980.00 |
| Dec 31, 2020 | 162,970.00 |
| Dec 31, 2020 | 162,970.00 |
| Dec 31, 2019 | 84,068.00 |
| Dec 31, 2019 | 84,068.00 |
| Dec 31, 2018 | 30,276.00 |
| Dec 31, 2018 | 30,276.00 |
| Dec 31, 2017 | 63,264.00 |
| Dec 31, 2017 | 63,264.00 |
| Dec 31, 2016 | 59,703.00 |
| Dec 31, 2016 | 59,703.00 |
| Dec 31, 2015 | 24,463.00 |
| Dec 31, 2015 | 24,463.00 |
| Sep 30, 2014 | 6,000.00 |
| Sep 30, 2014 | 6,000.00 |
| Jun 30, 2014 | 6,000.00 |
| Jun 30, 2014 | 6,000.00 |
| Dec 31, 2013 | 4,998.00 |
| Dec 31, 2013 | 4,998.00 |
| Sep 30, 2013 | 4,998.00 |
| Sep 30, 2013 | 4,998.00 |
| Jun 30, 2013 | 24,594.00 |
| Jun 30, 2013 | 24,594.00 |
| Dec 31, 2012 | 5,000.00 |
| Dec 31, 2012 | 5,000.00 |
| Dec 31, 2011 | 3,333.00 |
| Dec 31, 2011 | 3,333.00 |
| Dec 31, 2010 | 33,333.00 |
| Dec 31, 2010 | 33,333.00 |